Wednesday, 28 March 2018 17:57

New mechanism of drug resistance discovered in Pseudomonas aeruginosa

Written by 
Published in mBiosphere

Researchers have discovered a new type of antibiotic resistance against the common antibiotic ciprofloxacin. The resistance was discovered in the opportunistic pathogen Pseudomonas aeruginosa and is described in the journal Antimicrobial Agents and Chemotherapy.

AACJournal: Novel ciprofloxacin-modifying enzyme (CrpP) encoded by the Pseudomonas aeruginosa pUM505 plasmid

The new mechanism complements an already full arsenal that bacteria have to fight ciprofloxacin. Ciprofloxacin, or CIP, is a quinolone, which acts by locking DNA topoisomerase and gyrase enzymes in place as they nick DNA to be unwound. The accumulation of these enzyme-DNA complexes leads to cell death. To avoid CIP-mediated death, cells can alter the intracellular concentration by decreasing porin expression or increasing efflux via membrane-bound pumps. Cells can prevent CIP binding to its target, or alter the drug by adding an acetyl group. In the new research, first author Victor Chávez-Jacobo and senior scientist Martha Ramírez-Díaz describe a novel type of alteration: the addition of a phosphoryl group to CIP.

Table showing E.coli and P.aeruginosa drug resistance with and without CrpPDrug susceptibility of P. aeruginosa and E. coli with and without crpP expression. Source.

The scientific team first observed that CIP resistance was transferred by the plasmid pUM505, a plasmid originally identified in a clinical isolate and well-characterized for its virulence and resistance-conferring sequences. To identify the gene responsible for CIP phosphorylation, the scientific team analyzed the gene sequences encoded and noted homology between one gene, orf131 (renamed crpP), and an aminoglycoside transferase from Mycobacterium smegmatis. They tested crpP function by expressing it in Escherichia coli or P. aeruginosa and demonstrating an increase in CIP minimal inhibitory concentrations (MICs). P. aeruginosa expressing crpP had increases in other quinolone-family drug MICs, but neither expression in E. coli nor P. aeruginosa affected the MIC of other antibiotics, including aminoglycosides (see table, right). Liquid chromatography-tandem mass spectrometry studies on CIP incubated with purified CrpP protein determined that the resistance was due to phosphorylation of the drug.

Plasmid-encoded resistance is more easily spread between bacterial strains and species than chromosomally-encoded resistance, making the discovery of crpP on a plasmid that much more frightening. That means this discovery is not only dangerous for those suffering P. aeruginosa infections, but that the gene could be passed to related organisms, leading to the spread CIP resistance. The good news is that identification of the gene will make surveillance for resistance easier, hopefully stopping its spread before having a large impact in the clinic.


Want to hear more about the latest in antimicrobial resistance?

Register today for ASM Microbe 2018 to meet with fellow scientists and discuss cutting-edge research!

Last modified on Friday, 30 March 2018 17:33
Julie Wolf

Julie Wolf is the ASM Science Communications Specialist. She contributes to the ASM social media and blog network and hosts the Meet the Microbiologist podcast. She also runs workshops at ASM conferences to help scientists improve their own communication skills. Follow Julie on Twitter for more ASM and microbiology highlights at @JulieMarieWolf.

Julie earned her Ph.D. from the University of Minnesota, focusing on medical mycology and infectious disease. Outside of her work at ASM, she maintains a strong commitment to scientific education and teaches molecular biology at the community biolab, Genspace. She lives in beautiful New York City.